These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 28688841)
21. Understanding and modulating the MR1 metabolite antigen presentation pathway. McWilliam HEG; Salio M Mol Immunol; 2021 Jan; 129():121-126. PubMed ID: 33293099 [TBL] [Abstract][Full Text] [Related]
22. T cell receptor diversity, specificity and promiscuity of functionally heterogeneous human MR1-restricted T cells. Lepore M; Lewinsohn DA; Lewinsohn DM Mol Immunol; 2021 Feb; 130():64-68. PubMed ID: 33360378 [TBL] [Abstract][Full Text] [Related]
23. MR1-restricted T cells: the new dawn of cancer immunotherapy. Wang Z; Wang M; Chen J; Zhang L; Zhang L; Yu L Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33185693 [TBL] [Abstract][Full Text] [Related]
25. Recognition of the antigen-presenting molecule MR1 by a Vδ3 Rice MT; von Borstel A; Chevour P; Awad W; Howson LJ; Littler DR; Gherardin NA; Le Nours J; Giles EM; Berry R; Godfrey DI; Davey MS; Rossjohn J; Gully BS Proc Natl Acad Sci U S A; 2021 Dec; 118(49):. PubMed ID: 34845016 [TBL] [Abstract][Full Text] [Related]
26. Detection, Expansion, and Isolation of Human MAIT Cells. Liu Y; Wang W; Wu X; Weng X Methods Mol Biol; 2020; 2111():285-293. PubMed ID: 31933215 [TBL] [Abstract][Full Text] [Related]
27. Opsonization-Enhanced Antigen Presentation by MR1 Activates Rapid Polyfunctional MAIT Cell Responses Acting as an Effector Arm of Humoral Antibacterial Immunity. Boulouis C; Gorin JB; Dias J; Bergman P; Leeansyah E; Sandberg JK J Immunol; 2020 Jul; 205(1):67-77. PubMed ID: 32434941 [TBL] [Abstract][Full Text] [Related]
29. Virus-Mediated Suppression of the Antigen Presentation Molecule MR1. McSharry BP; Samer C; McWilliam HEG; Ashley CL; Yee MB; Steain M; Liu L; Fairlie DP; Kinchington PR; McCluskey J; Abendroth A; Villadangos JA; Rossjohn J; Slobedman B Cell Rep; 2020 Mar; 30(9):2948-2962.e4. PubMed ID: 32130899 [TBL] [Abstract][Full Text] [Related]
30. Potent Immunomodulators Developed from an Unstable Bacterial Metabolite of Vitamin B2 Biosynthesis. Mak JYW; Rivero RJD; Hoang HN; Lim XY; Deng J; McWilliam HEG; Villadangos JA; McCluskey J; Corbett AJ; Fairlie DP Angew Chem Int Ed Engl; 2024 Jul; 63(31):e202400632. PubMed ID: 38679861 [TBL] [Abstract][Full Text] [Related]
31. Functional Heterogeneity and Antimycobacterial Effects of Mouse Mucosal-Associated Invariant T Cells Specific for Riboflavin Metabolites. Sakala IG; Kjer-Nielsen L; Eickhoff CS; Wang X; Blazevic A; Liu L; Fairlie DP; Rossjohn J; McCluskey J; Fremont DH; Hansen TH; Hoft DF J Immunol; 2015 Jul; 195(2):587-601. PubMed ID: 26063000 [TBL] [Abstract][Full Text] [Related]
32. The effects of 5-OP-RU stereochemistry on its stability and MAIT-MR1 axis. Matsuoka T; Motozono C; Hattori A; Kakeya H; Yamasaki S; Oishi S; Ohno H; Inuki S Chembiochem; 2021 Feb; 22(4):672-678. PubMed ID: 33034934 [TBL] [Abstract][Full Text] [Related]
33. Role of CD1d- and MR1-Restricted T Cells in Asthma. Iwamura C; Nakayama T Front Immunol; 2018; 9():1942. PubMed ID: 30210497 [TBL] [Abstract][Full Text] [Related]
34. Diverse MR1-restricted T cells in mice and humans. Koay HF; Gherardin NA; Xu C; Seneviratna R; Zhao Z; Chen Z; Fairlie DP; McCluskey J; Pellicci DG; Uldrich AP; Godfrey DI Nat Commun; 2019 May; 10(1):2243. PubMed ID: 31113973 [TBL] [Abstract][Full Text] [Related]
35. Synthesis, stabilization, and characterization of the MR1 ligand precursor 5-amino-6-D-ribitylaminouracil (5-A-RU). Li K; Vorkas CK; Chaudhry A; Bell DL; Willis RA; Rudensky A; Altman JD; Glickman MS; Aubé J PLoS One; 2018; 13(2):e0191837. PubMed ID: 29401462 [TBL] [Abstract][Full Text] [Related]
36. The Toll-like receptor 9 signalling pathway regulates MR1-mediated bacterial antigen presentation in B cells. Liu J; Brutkiewicz RR Immunology; 2017 Oct; 152(2):232-242. PubMed ID: 28518215 [TBL] [Abstract][Full Text] [Related]